Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | CASP1 | P29466 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 2/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | RAD52 | P43351 | 1/20 | 0.40 |
| ▸ | NCF1 | P14598 | 3/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5036101 | 1.00 | MAP2K7 (0.48) | MAP2K7ALDH1A1GAAHPGDCASP1 | |
| SCHEMBL5037356 | 0.87 | ADORA2A (0.41) | MAP2K7ALDH1A1GAAHPGDCASP1 | |
| SCHEMBL5037350 | 0.87 | ADORA2A (0.41) | MAP2K7ALDH1A1GAAHPGDCASP1 | |
| SCHEMBL5022748 | 0.87 | ACVR1 (0.40) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5025400 | 0.87 | CCNE2 (0.42) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5521214 | 0.87 | ACVR1 (0.40) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5521204 | 0.87 | ACVR1 (0.40) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5084730 | 0.87 | CCNE2 (0.42) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL5022740 | 0.87 | ACVR1 (0.40) | MAP2K7ACVR1CCNE2CDK4CCND1 | |
| SCHEMBL27597784 | 0.83 | MTOR (0.41) | MAP2K7ACVR1KDM4EGLACCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| EP-1395564-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2004-03-10 | — | — | EP | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002094789-A1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | F. HOFFMANN-LA ROCHE AG (CH) | 2002-11-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAP2K7 2737/4885ALDH1A1 4803/4885GAA 826/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | MAP2K7 2737/4885ALDH1A1 4803/4885GAA 826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.